Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Date:9/22/2009

deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 22, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through lice
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
2. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
3. ER Doctor Demonstrates Breast Pump on Live TV with Patented New Freemie Hands-Free System
4. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
5. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
6. Abbott HIV Test Demonstrates Earlier Disease Detection
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
8. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
9. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
10. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
11. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Md. (PRWEB) September 17, 2014 ... Comprehensive Two-Dimensional Liquid Chromatograph (2D-LC), which offers ... complex sample matrices. The system provides a ... sample analytes, which is beneficial to scientists ... extracts, and natural products. , Comprehensive 2D-LC ...
(Date:9/17/2014)... Pa. , Sept. 17, 2014 BioClinica®, ... and eClinical Solutions, today announced three of its experts ... for Clinical Data Management to be held September ... Nevada . The Company also announced the innovative ... raise overall quality in clinical trials acquired earlier this ...
(Date:9/17/2014)... , Sept. 17, 2014 Hussey Copper ... MD-Cu 29 antimicrobial copper, announces Gilmour Academy Ice ... the first EPA-registered antimicrobial solid touch surface to help ... a reasonably priced surface that kills greater than 99.9% ... of exposure. 1 , ...
(Date:9/17/2014)... 2014 RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... it has been granted a patent by the ... unique delivery system for delivering its "original" RNAi ... the treatment of diseases with an inflammatory component. ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... March 25 Accera, Inc., a biotechnology company delivering ... announced that the company will be participating at two ... and CEO, will speak at the 2nd Annual BIO ... at the Sheraton Boston Hotel in Boston, MA. On ...
... 25 Shire plc (LSE: SHP, NASDAQ:, SHPGY ... Report and Accounts in respect of the year ended ... has previously announced unaudited full,year 2008 results, prepared in ... year earnings announcement on February 19,2009. , ...
... JOSEPH, Mich., and RALEIGH, N.C., March 25 ... grade televisions and communications solutions to hospitals, today announced ... part of the health system,s strategy to enhance the ... with Lakeland,s vision of improving the hospital experience by ...
Cached Biology Technology:Accera, Inc. to Present at Upcoming Investor Conferences 2Publication of Shire plc's Annual Report 2008 2Publication of Shire plc's Annual Report 2008 3Publication of Shire plc's Annual Report 2008 4Publication of Shire plc's Annual Report 2008 5Publication of Shire plc's Annual Report 2008 6Publication of Shire plc's Annual Report 2008 7Publication of Shire plc's Annual Report 2008 8Publication of Shire plc's Annual Report 2008 9Publication of Shire plc's Annual Report 2008 10Publication of Shire plc's Annual Report 2008 11Publication of Shire plc's Annual Report 2008 12Publication of Shire plc's Annual Report 2008 13Publication of Shire plc's Annual Report 2008 14Publication of Shire plc's Annual Report 2008 15Publication of Shire plc's Annual Report 2008 16Publication of Shire plc's Annual Report 2008 17Publication of Shire plc's Annual Report 2008 18Publication of Shire plc's Annual Report 2008 19Publication of Shire plc's Annual Report 2008 20Publication of Shire plc's Annual Report 2008 21Publication of Shire plc's Annual Report 2008 22Publication of Shire plc's Annual Report 2008 23Publication of Shire plc's Annual Report 2008 24Publication of Shire plc's Annual Report 2008 25Publication of Shire plc's Annual Report 2008 26Publication of Shire plc's Annual Report 2008 27Publication of Shire plc's Annual Report 2008 28Publication of Shire plc's Annual Report 2008 29Publication of Shire plc's Annual Report 2008 30Publication of Shire plc's Annual Report 2008 31Publication of Shire plc's Annual Report 2008 32Publication of Shire plc's Annual Report 2008 33TeleHealth Services and Lakeland HealthCare Connect to Create Outstanding Patient Experience 2TeleHealth Services and Lakeland HealthCare Connect to Create Outstanding Patient Experience 3
(Date:9/16/2014)... biology taught us that we inherit certain traits from ... could change how these genes play out by taking ... That,s exactly what a team of researchers at ... through their research of epigenetics research. , Epigenetics ... modifying DNA and histone proteins, which prevent permanent mutations ...
(Date:9/16/2014)... has its own bacterial identity. That,s the conclusion of ... who studied the genetic fingerprints of bacteria on 57 ... "This study demonstrates for the first time that host ... strategies possess very different microbial communities on their leaves," ... researcher in the UO,s Institute of Ecology and Evolution ...
(Date:9/16/2014)... diameter chunk of rock hit the Yukatan peninsula near the ... of 100 teratons of TNT. It left a crater more ... earthquakes and volcanism are widely accepted to have wiped out ... mammals. But what happened to the plants on which the ... the University of Arizona reveals that the meteorite impact that ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... that the bacterium that causes dysentery uses a 'sword ... research published today in Science, the team from Imperial ... the bacteria which causes dysentery, is able to invade ... , They found that shigella was able to infect ...
... 99 percent of the genes in the adult body. That's ... of bacteria that normally live on and in us. , ... to researchers at the School of Medicine will help fill ... for isolating, sequencing and analyzing the genomes of "friendly" bacteria ...
... in the journal Blood, Yale scientists identify the molecular triggers ... expand into large populations of malignant lymphocytes. , CTCL is ... blood cells of the immune system. Finding CTCL triggering factors ... Director of the Yale Cancer Center, and professor and chair ...
Cached Biology News:W.M. Keck Foundation funds study of friendly microbes 2W.M. Keck Foundation funds study of friendly microbes 3Source of molecular triggers in cutaneous T cell lymphoma identified 2
HOXC11 Antibody...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Biology Products: